New cholera vaccine trial aims to protect families in High-Risk areas
NCT ID NCT07509047
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new cholera vaccine (OSP:rTTHc CCV) in 390 healthy adults and children aged 1 to 45 in a region where cholera is common. The goal is to see if the vaccine is safe and triggers a strong immune response. Some participants get the vaccine with or without an adjuvant (alum), while others get a standard cholera vaccine or a placebo. Results will help decide the best dose and schedule for future use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OSP:rTTHc cholera conjugate vaccine (CCV) with or without aluminum phosphate adjuvant
- What this could lead to
- If successful, this could lead to a more effective cholera vaccine that protects adults and children with fewer doses.
- What could go wrong
- This is a phase II trial with 390 participants, so results are still early. The vaccine may not produce strong enough immunity or could have side effects not seen yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KAVI-Institute of Clinical Research, University
RECRUITINGNairobi, Kenyatta National Hospital Complex, 19676, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.